Public/Private Initiative To Help FDA Modernize Guidance For Clinical Trials
Executive Summary
Output from the Clinical Trials Transformation Initiative, whose executive board was named May 5, is expected to lead to new FDA clinical trial guidance
You may also be interested in...
FDA Compliance Office Wants To Find Clinical Trial Problems In Time To Correct Them
The agency is seeking a quality-by-design approach to clinical trials so sponsors can identify potential risks to patient safety and trial implementation up-front and take steps to avoid them.
Reagan-Udall Foundation Approaches The Starting Line; Next Step Is Funding
The FDA Amendments Act, which reauthorized the user fee program and gave FDA broad new powers to ensure drug safety, has given the agency an abundance of oversight functions to organize, but also has provided the agency an outside partner: The Reagan-Udall Foundation
Clinical Trial Modernization, Outsourcing Concerns Are Focus Of FDA/Duke Effort
In an FDA-Duke University Medical Center partnership to modernize the way clinical trials are conducted, close attention will be paid to the increase of outsourcing and off-shoring clinical trials